Akanda Corp. (AKAN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Akanda Corp. (AKAN) trades at $12.00 with AI Score 44/100 (Grade C). Akanda Corp. cultivates, manufactures, and distributes cannabis products in the United Kingdom, Lesotho, and internationally. Market cap: $388,392, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for AKAN: AKAN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AKAN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AKAN: the 1 perspectives are evenly split.
How is this calculated? →Akanda Corp. (AKAN) Healthcare & Pipeline Overview
Akanda Corp. operates within the specialty and generic drug manufacturing sector, focusing on the cultivation, manufacture, and distribution of cannabis products. With operations in the UK, Lesotho, and internationally, Akanda aims to supply medical and wellness markets, facing competition in a rapidly evolving industry.
What Is the Investment Thesis for AKAN?
Akanda Corp. presents a high-risk, high-reward investment opportunity in the emerging cannabis market. With a negative P/E ratio of -0.15 and a substantial negative profit margin of -619.5%, the company's financial performance raises concerns. However, its high gross margin of 73.3% suggests potential profitability with improved operational efficiency. Growth catalysts include expansion into new markets and the introduction of innovative cannabis-based products. The company's success hinges on navigating regulatory hurdles and securing a significant market share in a competitive landscape. Investors should carefully weigh the potential for significant returns against the inherent risks associated with the cannabis industry and Akanda's current financial position.
Based on FMP financials and quantitative analysis
AKAN Key Highlights
- Market capitalization of 388K indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -0.15 reflects current unprofitability, requiring careful monitoring of future earnings potential.
- Profit margin of -619.5% signals substantial operational challenges and the need for aggressive cost management.
- Gross margin of 73.3% suggests strong pricing power and efficient production, providing a foundation for future profitability.
- Beta of 1.69 indicates higher volatility compared to the market, reflecting the speculative nature of the cannabis industry.
Who Are AKAN's Competitors?
AKAN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HSCS HeartSciences Inc. | $2.71 | -2.69% | $5.88M | — |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AKAN's Key Strengths?
- Strategic locations in the United Kingdom and Lesotho.
- High gross margin of 73.3%.
- Focus on medical and wellness markets.
- Vertical integration from cultivation to distribution.
What Are AKAN's Weaknesses?
- Negative P/E ratio of -0.15.
- Substantial negative profit margin of -619.5%.
- Limited operating history as incorporated in 2021.
- Small employee base of 46.
What Could Drive AKAN Stock Higher?
- Expansion into new European markets by Q4 2026, pending regulatory approvals.
- Development and launch of new cannabis-based products for medical and wellness applications throughout 2026.
- Strategic partnerships with established players in the cannabis industry to expand market reach.
What Are the Key Risks for AKAN?
- Financial-distress signal — its Altman Z-Score of -28.08 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-58.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Evolving and complex regulatory environment impacting operations and market access.
- Intense competition in the cannabis industry leading to price pressures and reduced market share.
- Fluctuations in cannabis prices affecting profitability and revenue projections.
- Changes in government policies regarding cannabis legalization and regulation.
What Are the Growth Opportunities for AKAN?
- Expansion into new European markets: Akanda has the opportunity to expand its distribution network into additional European countries as regulations evolve and cannabis legalization progresses. The European cannabis market is projected to reach multi-billion dollar valuations by 2030, offering substantial revenue potential. Successful market entry requires navigating diverse regulatory frameworks and establishing strategic partnerships with local distributors.
- Development of innovative cannabis-based products: Akanda can drive growth by investing in research and development to create innovative cannabis-based products, such as novel formulations for medical applications or unique wellness offerings. The market for specialized cannabis products is growing rapidly, driven by increasing consumer awareness and demand for targeted solutions. Successful innovation requires a deep understanding of consumer needs and scientific advancements in cannabis research.
- Strategic partnerships and acquisitions: Akanda can accelerate its growth by forming strategic partnerships with established players in the cannabis industry or acquiring complementary businesses. Partnerships can provide access to new markets, technologies, or distribution channels, while acquisitions can expand Akanda's product portfolio and market share. Successful partnerships and acquisitions require careful due diligence and integration planning.
- Focus on medical cannabis market: Akanda can capitalize on the growing demand for medical cannabis products by focusing on developing and marketing cannabis-based therapies for specific medical conditions. The medical cannabis market is driven by increasing acceptance among healthcare professionals and patients, as well as growing evidence of the therapeutic benefits of cannabis. Success in this market requires rigorous clinical research and adherence to strict regulatory standards.
- Leveraging Lesotho operations for cost-effective cultivation: Akanda can leverage its operations in Lesotho to cultivate cannabis at a lower cost compared to other regions. Lesotho offers favorable climatic conditions and lower labor costs, providing a competitive advantage in the production of high-quality cannabis. Successful cultivation in Lesotho requires effective supply chain management and adherence to international quality standards.
What Opportunities Does AKAN Have?
- Expansion into new European markets.
- Development of innovative cannabis-based products.
- Strategic partnerships and acquisitions.
- Increasing acceptance of medical cannabis.
What Threats Does AKAN Face?
- Evolving and complex regulatory environment.
- Intense competition in the cannabis industry.
- Fluctuations in cannabis prices.
- Potential changes in government policies.
What Are AKAN's Competitive Advantages?
- Strategic locations in the United Kingdom and Lesotho.
- Focus on high-quality cannabis products.
- Vertical integration from cultivation to distribution.
- Expertise in navigating complex regulatory environments.
What Does AKAN Do?
Akanda Corp. was incorporated in 2021 and is headquartered in New Romney, United Kingdom. The company operates through its subsidiaries, engaging in the cultivation, manufacture, and distribution of cannabis products. Akanda focuses on supplying cannabis-based medical and wellness products to meet the growing demand in the United Kingdom, Lesotho, and other international markets. The company's business model encompasses the entire value chain, from cultivation to distribution, allowing for control over product quality and supply. Akanda aims to establish itself as a key player in the emerging cannabis market by leveraging its strategic locations and focusing on high-quality products. The company's operations in Lesotho provide access to cost-effective cultivation, while its presence in the United Kingdom allows for distribution to a significant consumer base. Akanda is navigating a complex regulatory landscape as it seeks to expand its market reach and product offerings.
What Products and Services Does AKAN Offer?
- Cultivates cannabis in Lesotho.
- Manufactures cannabis products in the United Kingdom.
- Distributes cannabis products in the United Kingdom.
- Supplies cannabis-based medical products.
- Supplies cannabis-based wellness products.
- Operates internationally.
How Does AKAN Make Money?
- Cultivation of cannabis in Lesotho for cost-effective production.
- Manufacturing of cannabis products in the United Kingdom to meet local demand.
- Distribution of cannabis products through established channels.
- Focus on medical and wellness markets to capitalize on growing demand.
What Industry Does AKAN Operate In?
Akanda Corp. operates in the rapidly evolving cannabis industry, which is experiencing significant growth due to increasing legalization and acceptance of cannabis for medical and recreational purposes. The market is characterized by intense competition, with numerous companies vying for market share. Akanda competes with established players and emerging startups, all seeking to capitalize on the growing demand for cannabis products. The industry is subject to evolving regulations and varying legal frameworks across different jurisdictions, creating both opportunities and challenges for companies like Akanda. Companies must navigate these complexities to establish a sustainable and profitable business model.
Who Are AKAN's Key Customers?
- Patients seeking medical cannabis treatments.
- Consumers interested in cannabis-based wellness products.
- Distributors and retailers in the United Kingdom.
- International partners in select markets.
Akanda Corp. (AKAN) Valuation Context
Valued at 388K, AKAN is classified as a micro-cap stock. Relative to its peer group, AKAN's quantitative score of 44/100 is below the peer average of 68/100.
AKAN Revenue & Earnings Trend
In Q4 2025, AKAN generated $258K in top-line revenue, marking a sequential decrease of 28.2%. The company recorded a net loss of $44.8M, with diluted EPS of $-655.12. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely.
Company Profile
Akanda Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in New Romney, GB. The company is led by CEO Katharyn Field. AKAN has traded publicly since 2022.
ROE -59%Key Financial Metrics
Return on equity for Akanda Corp. stands at -58.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -35.9%, showing how much profit it generates from its asset base. A current ratio of 1.25 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 2/9Financial Health
Akanda Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -28.08 places it in the distress zone, a signal of elevated financial risk.
AKAN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Akanda's future performance, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting Akanda's innovative approach to cannabis products, attracting interest from investors.
- Market perception has improved as Akanda continues to expand its product offerings, positioning itself well in a growing industry.
- Recent partnerships and collaborations have been announced, enhancing Akanda's market presence and operational capabilities.
Bear Case
- Despite positive insider activity, broader market volatility has raised concerns about the sustainability of Akanda's growth in the current economic climate.
- Social sentiment remains mixed; some community members express skepticism about Akanda's ability to compete against larger, established players in the cannabis sector.
- Recent regulatory challenges in the cannabis industry could pose risks to Akanda's operations and market expansion plans.
- There are ongoing concerns regarding Akanda's financial health, with some analysts questioning its ability to maintain profitability amid rising operational costs.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $258,075 | -$45M | -$655.12 |
| Q4 2024 | $359,658 | -$1M | -$49.20 |
| Q2 2024 | $477,006 | -$3M | -$355.20 |
Based on FMP financials and quantitative analysis
AKAN Latest News
-
12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga · Jun 22, 2026
-
12 Health Care Stocks Moving In Friday's Intraday Session
benzinga · Jun 12, 2026
-
'White House Pushes Congress To Keep Hemp CBD Products Legal By Amending Broad Ban That's Set To Take Effect Later This Year' - Marijuana Moment
benzinga · Jun 5, 2026
-
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga · Jun 1, 2026
AKAN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AKAN.
Price Targets
Wall Street price target analysis for AKAN.
AKAN MoonshotScore
What does this score mean?
The MoonshotScore rates AKAN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Intraday Session
'White House Pushes Congress To Keep Hemp CBD Products Legal By Amending Broad Ban That's Set To Take Effect Later This Year' - Marijuana Moment
12 Health Care Stocks Moving In Monday's Intraday Session
Latest Akanda Corp. Analysis
Leadership: Katharyn Field
CEO
Katharyn Field serves as the CEO of Akanda Corp., managing a team of 46 employees. Her background includes experience in the cannabis industry, with a focus on strategic planning, operational management, and market development. She has a proven track record of building and scaling businesses in highly regulated environments. Her expertise spans across cultivation, manufacturing, and distribution, enabling her to lead Akanda Corp. effectively.
Track Record: Under Katharyn Field's leadership, Akanda Corp. has focused on establishing a vertically integrated business model, expanding its operations in the United Kingdom and Lesotho. She has overseen the development of new cannabis-based products and the expansion of the company's distribution network. Her strategic decisions have been instrumental in navigating the complex regulatory landscape and positioning Akanda Corp. for future growth.
What Investors Ask About Akanda Corp. (AKAN) — Healthcare
What does Akanda Corp. do?
Akanda Corp. cultivates, manufactures, and distributes cannabis products in the United Kingdom, Lesotho, and internationally. The company focuses on supplying cannabis-based medical and wellness products, aiming to capitalize on the growing demand for these products in various markets. Akanda's operations encompass the entire value chain, from cultivation to distribution, allowing for control over product quality and supply.
What do analysts say about AKAN stock?
As of March 17, 2026, there is no available analyst coverage for AKAN stock. Given the company's micro-cap status and limited operating history, analyst coverage may be sparse. Investors should conduct their own due diligence and carefully consider the risks and opportunities associated with investing in AKAN. Key valuation metrics include market capitalization, P/E ratio, profit margin, and gross margin. Growth considerations include expansion into new markets, development of innovative products, and strategic partnerships.
What are the main risks for AKAN?
Akanda Corp. faces several key risks, including the evolving and complex regulatory environment surrounding the cannabis industry. Changes in regulations could impact the company's operations and market access. Intense competition in the cannabis industry could lead to price pressures and reduced market share. Fluctuations in cannabis prices could affect profitability and revenue projections. Additionally, potential changes in government policies regarding cannabis legalization and regulation pose a risk to the company's business model.
How does Akanda Corp. ensure the quality and safety of its cannabis products?
Akanda Corp. prioritizes the quality and safety of its cannabis products through rigorous testing and adherence to strict regulatory standards. The company implements quality control measures throughout the entire value chain, from cultivation to manufacturing and distribution. Akanda also invests in state-of-the-art facilities and equipment to ensure the highest standards of product quality. By maintaining a focus on quality and safety, Akanda aims to build trust with consumers and establish a reputation for excellence in the cannabis industry.
What revenue streams does Akanda Corp. have in healthcare?
Akanda Corp.'s revenue streams in healthcare primarily consist of sales of cannabis-based medical products to patients and healthcare providers. The company focuses on developing and marketing cannabis-based therapies for specific medical conditions, such as chronic pain, anxiety, and epilepsy. Akanda also generates revenue through partnerships with healthcare organizations and research institutions. The company's revenue streams are expected to grow as the medical cannabis market expands and acceptance among healthcare professionals increases.
What are the key factors to evaluate for AKAN?
Akanda Corp. (AKAN) holds an AI score of 44/100 (low). Not financial advice.
How frequently does AKAN data refresh on this page?
AKAN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AKAN's recent stock price performance?
Akanda Corp. (AKAN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strategic locations in the United Kingdom and Lesotho. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Akanda Corp. due to its micro-cap status and limited operating history.
- Financial data is based on available information and may not be comprehensive.
- AI analysis is pending and may provide additional insights in the future.